ebook: Accelerate vaccine development
Our comprehensive portfolio suite is designed to optimize your productivity to get safe and efficacious vaccines and therapeutics to market faster.
List view / Grid view
Our comprehensive portfolio suite is designed to optimize your productivity to get safe and efficacious vaccines and therapeutics to market faster.
Researchers have designed a new nanoparticle-based vaccine against Ebola that has shown promise in mice and rabbits.
A new vaccine has shown promise at protecting monkeys and mice from COVID-19, its variants and other coronaviruses.
11 May 2021 | By PerkinElmer
Get the Big Picture and listen to Pharma thought leaders how they view CETSA® and its impact on their Drug Discovery.
Epithelial cell communication depends on the side of the cell, which could have implications for understanding how cancer spreads.
Exosomes containing salmonella antigens were administered to the mice, enabling the models to develop antibodies against the bacteria.
The UK Government will invest £29.3 million to test the effectiveness of COVID-19 vaccines against variants in 3,000 blood samples a week.
Researchers have found that over 80 percent of antibodies target sections of the SARS-CoV-2 Spike protein other than the RBD.
Gain more insight into immune-tumor interactions and learn how antibody detection techniques like multiplexing is advancing immunotherapies.
In this short video we show an example of a 3D airway organoid model along with some interesting ways to get the most out of this type of assay.
The UK has launched the Pandemic Preparedness Partnership which will advise the G7 Presidency how to reduce vaccine development time from 300 to 100 days.
A candidate vaccine has shown potential against MERS in non-human primates, when administered intradermally.
Accelerate your research with an upgradeable platform. Benefit from a fluidic-free assay format for easy and fast kinetics or analyte quantitation.
Biliverdin attaches to a region of the SARS-CoV-2 Spike protein, stabilising it so that it is not able to expose its structure to antibodies, a new study has shown.
Using newly developed assays, researchers have characterised the antibody response of individuals infected with SARS-CoV-2.